ArticleFrontiers in pharmacology2023

Does China's centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model.

Yang Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.